MAPK3 and cancer: Together, results in Figure 5 suggest that BST-2 dimerization promotes ERK1/2 activation, BIM phosphorylation/degradation and inhibition of Cas3 activation that culminate in enhanced anoikis resistance – a phenotype required by cancer cells to survive in circulation.